Taking aim at disease

February 16, 2024, 3:02PMNuclear NewsKristi Nelson Bumpus
ORNL radioisotope manufacturing coordinator Jillene Sennon-Greene places a shipment vial of actinium-225 inside the dose calibrator to confirm its activity is within customer specifications. (Photo: Carlos Jones/ORNL, DOE)

On August 2, 1946, 1 millicurie of the isotope carbon-14 left Oak Ridge National Laboratory, bound for the Barnard Free Skin and Cancer Hospital in St. Louis, Mo.

That tiny amount of the radioisotope was purchased by the hospital for use in cancer studies. And it heralded a new peacetime mission for ORNL, built just a few years earlier for the production of plutonium from uranium for the Manhattan Project.

To continue reading, log in or create a free account!

Related Articles

On moving fast and breaking things

March 16, 2026, 9:33AMNuclear NewsCraig Piercy

So much of what is happening in federal nuclear policy these days seems driven by a common approach popularized in the technology sector. Silicon Valley calls it “move fast and break...

Webinar highlights Gen IV reactors

March 16, 2026, 7:31AMANS News

The American Nuclear Society recently hosted a new webinar in its ongoing Educator Training series titled “Perspectives on Generation IV Reactors.” It was led by Edward A. Friedman,...

Aalo Atomics discusses the road ahead

March 12, 2026, 1:13PMNuclear News

Yasir Arafat, president and chief technology officer of Aalo Atomics, participated in the first day of sessions at the Nuclear Regulatory Commission’s annual Regulatory Information...

Return of the HB Line at SRS

March 11, 2026, 5:02PMNuclear News

The Department of Energy is bringing the HB Line facility at the Savannah River Site back on line to recycle surplus plutonium and produce uranium-plutonium mixed oxide (MOX) fuel for advanced...